BioMarin Pharmaceutical (HAM:BM8) Research & Development: €808 Mil (TTM As of Mar. 2026)


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
79 GF Score
Price €48.79
GF Value €72.11
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Research & Development?

BioMarin Pharmaceutical HAM:BM8 -3.65% 79 Research & Development is €808 Mil as of Mar. 2026. GuruFocus rates HAM:BM8 with a GF Score™ of 79/100 and a GF Value™ of €72.11. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. BioMarin Pharmaceutical's Research & Development for the three months ended in Mar. 2026 was €155 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €808 Mil.

BioMarin Pharmaceutical  (HAM:BM8) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BioMarin Pharmaceutical Research & Development Related Terms

BioMarin Pharmaceutical Research & Development Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Research & Development Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 556.48 613.23 684.79 713.56 787.33

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 146.83 139.85 348.88 164.32 154.66
HAM:BM8
79GF Score
BioMarin Pharmaceutical Inc HAM:BM8
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €808 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €808 Mil mean?
BioMarin Pharmaceutical (HAM:BM8) has a Research & Development of €808 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Research & Development too high?
BioMarin Pharmaceutical's current Research & Development is €808 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Research & Development compare to ARWR and MDGL?
BioMarin Pharmaceutical's Research & Development of €808 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Research & Development is €808 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current Research & Development of €808 Mil. The stock's GF Value™ is €72.11, compared to a current price of €48.79 — trading 32.3% below its estimated fair value. The current Research & Development is €808 Mil. BioMarin Pharmaceutical's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current Research & Development is €808 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €48.79 is trading 32.3% below its estimated GF Value™ of €72.11.

Key valuation signals for HAM:BM8:

  • Research & Development: €808 Mil
  • GF Value™: €72.11 vs. price of €48.79 (32.3% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score

Get the complete analysis for HAM:BM8

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.79
Price
€72.11
GF Value